Cardiovascular Disease (CVD) was flagged by the NHS as the most prominent condition in which lives could be saved – with plans of preventing 150,000 heart attacks over a decade. What does the technology look like which can achieve this?
The 2019 long-term plan from the NHS was clear in its intentions to prevent thousands of heart attacks, via health technology which can enable early detection, and increasing access to testing in primary care.
Numbers are expected to reduce by improving early detection and treatment of CVD, supporting people with heart failure (HF) and heart valve disease through increased access to testing in primary care.
2022 – Still work to be done
Fast forward to 2022, and current technology used in primary care, (the 12-Lead ECG), provides “limited diagnostic evidence” for many common heart problems
Testament to these limitations, medical malpractice claims reveal that in over 70% of all “failure to diagnose” claims, the ECG relied upon by the Healthcare Practitioner was “inconclusive” or “non-diagnostic.
All too often these findings are incorrectly interpreted as a “Normal ECG”, rather than as a disease ECG is not designed to detect. Few patients are aware of these limitations. Cardio-HART can address this unmet need.
Breakthrough cardio tech & AI
Cardio-HART is a medical innovation that overcomes those limitations by combining the diagnostic capabilities of an AI reported 12 Lead ECG, an eStethoscope and an Echocardiogram.
Using novel bio-signals, CHART findings cover ~95% of all common heart diseases, and its severity, including: heart failure (HFpEF, HFmrEF or HFrEF), and related structural (atrial and ventricular enlargement), functional (systolic and diastolic dysfunction) and valve abnormalities (stenosis or regurgitation).
The AI allows it to reach significantly higher sensitivity and specificity, with a capability for the early detection of CVD onset.
Unlike ECG, CHART can also prioritise patients based on severity.
This will dramatically change the pathway to secondary care from first come first served, to highest priority. Implementation of this new pathway will lead to more immediate access to treatment, and of high importance and impact, realise reductions in wait times and backlogs for echocardiography services in particular, and the associated secondary care costs.
Assisting heart failure patients
A patient seeing their doctor will undergo 3+ months of costly and time consuming testing before a clinical diagnosis of heart failure is made.
Then another three-t0-six month wait for echocardiography, to confirm and also test for valve disease present in 60% of cases of heart failure. Lastly, the cardiologist, and access to treatment.
Now imagine that CHART can detect both Heart Failure and Valve Disease on Day-1, when the patient first saw their doctor.
Access to treatment is immediate, or if urgent, sent to the front of the line to cardiology. Treatment would have started ~1-year earlier, reducing suffering and costs.
UK Biobank releases world’s largest single set of sequencing data
Listen: Longevity, Eastern wisdom and Western science
Fundamental principles of healthcare digital twins
Tackling the diagnostic testing sustainability problem
Gym-going men ‘unaware’ of protein risk to fertility
Anti-choke mug protects Parkinson’s patients
AI model predicts breast cancer risk without racial bias
TheHill secures UK gov funding and Barclays support to help advance digital innovation
Real time data collection changes the game for the stroke patient pathway
Inside BT’s mission to boost NHS connectivity
- Products4 weeks ago
Pioneering paediatric pressure ulcer mattress to be showcased at MEDICA 2023
- Diagnostics3 weeks ago
3D model will advance understanding of spinal injury pathology
- Opinion4 days ago
Why it’s time to revisit workplace mental health initiatives and make them work for everyone
- Biotech4 weeks ago
LiliumX unveils rebrand as Valink Therapeutics and appointment of new board and execs after securing $7.8m investment